Rhinitis companies are Abdi Ibrahim Pharmaceuticals, Lyra Therapeutics, Inmunotek, Iltoo Pharma, Advagene Biopharma, AOBiome, Sanofi, Hanmi Pharmaceutical, Emergo Therapeutics, Inimmune, Paradigm Biopharmaceuticals, Dong Wha Pharm, Siolta Therapeutics, Revelation Biosciences, Allergy Therapeutics, NeuCen BioMed, CSPC ZhongQi Pharmaceutical Technology, Biomay AG, and others.
The rhinitis treatment market is being propelled by factors such as rising prevalence, advancements in therapeutic approaches, increased awareness, and the continuous development of novel drugs. According to DelveInsight, more than 35 pharmaceutical and biotech companies are actively pursuing over 35 therapeutic candidates for rhinitis, spanning multiple stages of clinical and preclinical development. This reflects strong innovation and dedication toward addressing a significant public health concern.
DelveInsight’s “Rhinitis Pipeline Insight 2025” report offers a comprehensive and strategic assessment of the current R&D landscape. It explores clinical trial progress, emerging drug candidates, mechanisms of action, competitive dynamics, and major corporate initiatives. Serving as an essential resource, the report provides valuable insights for stakeholders—including researchers, healthcare investors, and decision-makers—into the evolving rhinitis therapeutics market and the scientific advancements shaping its future.
Explore the Cutting-Edge Landscape of Rhinitis Drug Development @ https://www.delveinsight.com/report-store/rhinitis-pipeline?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Key Takeaways from the Rhinitis Pipeline Report
-
DelveInsight’s Rhinitis pipeline report highlights a dynamic landscape with over 35 active companies developing more than 35 therapeutic candidates for rhinitis treatment.
-
In March 2025, the FDA approved Astepro (Azelastine Hydrochloride) nasal spray for over-the-counter use, marking it as the first nasal antihistamine available without a prescription for seasonal and perennial allergic rhinitis in adults and children aged 6 and above. Earlier, in August 2024, the FDA approved Neffy, an epinephrine nasal spray, offering a needle-free option for emergency treatment of severe allergic reactions, including anaphylaxis. Meanwhile, the FDA is reviewing the efficacy of oral phenylephrine, a widely used decongestant, and may remove it from the market due to concerns over its limited effectiveness, encouraging alternatives like nasal sprays and corticosteroids such as Flonase.
-
In March 2024, XHANCE (Fluticasone Propionate) nasal spray received FDA approval for treating chronic rhinosinusitis without nasal polyps in adults aged 18 and older. XHANCE is the first medication specifically approved for this condition, delivering corticosteroids directly to the nasal passages.
-
Key players advancing the rhinitis pipeline include Regeneron, Revolo Biotherapeutics, Anhui Palo Alto Pharmaceuticals, Abdi Ibrahim Pharmaceuticals, Lyra Therapeutics, Inmunotek, Iltoo Pharma, Advagene Biopharma, AOBiome, Sanofi, Hanmi Pharmaceutical, Emergo Therapeutics, Inimmune, Paradigm Biopharmaceuticals, Dong Wha Pharm, Siolta Therapeutics, Revelation Biosciences, Allergy Therapeutics, NeuCen BioMed, CSPC ZhongQi Pharmaceutical Technology, Biomay AG, and others.
-
Promising pipeline candidates under development include REGN1908-1909, IRL201104, and additional therapies aimed at improving rhinitis treatment outcomes.
Rhinitis Overview:
Rhinitis is a condition characterized by nasal congestion, runny nose or post-nasal drip, sneezing, and itching. It can arise from multiple causes and is typically classified as either allergic or non-allergic. Allergic rhinitis, commonly known as hay fever, occurs when the immune system overreacts to harmless substances like pollen, mold, dust mites, pet dander, or other environmental triggers, causing histamine release and inflammation that leads to typical allergy symptoms. Non-allergic rhinitis, in contrast, is not triggered by allergens and may result from irritants such as smoke, weather changes, or infections. Rhinitis often coexists with or precedes sinusitis, which presents with facial pressure, reduced sense of smell, and discolored nasal discharge. Diagnosis and management by an ENT specialist are recommended, with treatment options tailored to the cause, including avoiding triggers, medications, or allergen immunotherapy such as allergy shots or sublingual tablets.
Download the Rhinitis sample report to know in detail about the Rhinitis treatment market @ https://www.delveinsight.com/sample-request/rhinitis-pipeline?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Rhinitis Pipeline Analysis
The Rhinitis pipeline insights report 2025, provides insights into:
-
Provides comprehensive insights into key companies developing therapies in the Rhinitis Market.
-
Categorizes Rhinitis therapeutic companies by development stage: early, mid, and late-stage.
-
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.
-
Reviews emerging Rhinitis drugs under development based on:
-
Stage of development
-
Rhinitis Route of administration
-
Target receptor
-
Monotherapy vs. combination therapy
-
Rhinitis Mechanism of action
-
Molecular type
-
-
Offers detailed analysis of:
-
Company-to-company and company-academia collaborations
-
Rhinitis Licensing agreements
-
Funding and investment activities supporting future Rhinitis market advancement.
-
Unlock key insights into emerging Rhinitis therapies and market strategies here: https://www.delveinsight.com/report-store/rhinitis-pipeline?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Rhinitis Emerging Drugs
-
REGN1908-1909: Regeneron
REGN1908-1909 is a Phase III antibody therapy from Regeneron designed to target the Fel d 1 cat allergen and inhibit allergic reactions. Built using VelocImmune® technology, it is intended for the treatment of cat allergy–induced allergic rhinitis.
-
IRL201104: Revolo Biotherapeutics
IRL201104, based on a naturally occurring immune-regulatory protein, is designed to modulate the immune system and provide long-lasting allergy relief. It quickly decreases lung neutrophil infiltration following a bronchial challenge, although the effect is temporary. The therapy is currently being evaluated in Phase II trials for seasonal allergic rhinitis.
Rhinitis Pipeline Therapeutic Assessment
Rhinitis Assessment by Product Type
• Mono
• Combination
• Mono/Combination
Rhinitis By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Rhinitis Assessment by Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
Rhinitis Assessment by Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Download sample pages to get an in-depth assessment of the emerging Rhinitis therapies and key Rhinitis companies: https://www.delveinsight.com/sample-request/rhinitis-pipeline?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Table of Contents
1. Report Introduction
2. Executive Summary
3. Rhinitis Current Treatment Patterns
4. Rhinitis – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Rhinitis Late-Stage Products (Phase-III)
7. Rhinitis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Rhinitis Discontinued Products
13. Rhinitis Product Profiles
14. Rhinitis Key Companies
15. Rhinitis Key Products
16. Dormant and Discontinued Products
17. Rhinitis Unmet Needs
18. Rhinitis Future Perspectives
19. Rhinitis Analyst Review
20. Appendix
21. Report Methodology
Request the sample PDF to get detailed insights about the Rhinitis pipeline reports offerings: https://www.delveinsight.com/report-store/rhinitis-pipeline?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/